English
This article is from North American Journal of Medical Sciences , volume 3 . Abstract Background:: Advanced hepatocellular carcinoma (HCC) is a malignancy of global importance: it is the sixth most common cancer and the third most common cause of cancer-related mortality worldwide. Despite decades of efforts by many investigators, systemic chemotherapy or hormone therapy has failed to demonstrate improved survival in patients with HCC.. Ongoing studies are evaluating the efficacy and tolerability of combining Sorafenib with erlotinib and other targeted agents or chemotherapy. Aims:: On the basis of placebo-controlled, randomized phase III trials, Sorafenib has shown improved survival benefits in advanced HCC and has set a new standard for future clinical trials. The successful clinical development of Sorafenib in HCC has ushered in the era of molecularly targeted agents in this disease, which is discussed in this educational review. Material and Methods:: Many molecularly targeted agents that inhibit angiogenesis, epidermal growth factor receptor, and mammalian target of rapamycin are at different stages of clinical development in advanced HCC. Future research should continue to un
Sign in with your free account to read, download EPUBs or listen.
Ebook · Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. · Tazi, El Mehdi, Essadi, Ismail, M'rabti, Hind, Touyar, Anass, Errihani, PR Hassan · Internet Archive